Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Unknown Analyst
Period: Reporting periods mapped to calendar 2025 Q1 – 2026 Q1 (5 quarters; questions recorded in 3).
- Questions
- 4on tracked calls
- Challenge rate
- 0%none of 4 questionsLimited sample
- Companies
- 3questioned at least once
- Reporting periods
- 3with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 4 of 4 questions from 3 companies
IQVIQVIA2 questions · 2 reporting periods · 0 of 2 challenging
Calendar 2026 Q1
which areas were most surprising versus your internal expectations
Show response
Bousbib said organic Commercial growth doubled to 5%. Info (~30% of total) low single digits. Patient Solutions very strong double-digit growth. Analytics and Consulting best growth in three years with record pipeline. AI-driven innovation creating new demand rather than displacing. 10 new drug launches in Q1 fueling commercial activity.
Calendar 2025 Q2
how does TAS continue to earn through this environment? Is the real-world evidence strength and other areas of strength within TAS offsetting any weakness than any of the other subsegments
Show response
Bousbib said TAS recovery has been underway since Q3 2024, slightly better than expected. Real-world was the strongest at double-digit growth (~1/3 of TAS), rest was low to mid-single digits. Decision timelines improved 15% YoY. Win rate improved a couple of points YoY.
FISFidelity National Information Services1 question · 1 reporting period · 0 of 1 challenging
Calendar 2025 Q1
what would you consider the lowest hanging fruit from a cost synergy standpoint and any additional color you could provide on the rate in which you expect to realize these synergies
Show response
Stephanie identified three areas: duplicate vendor rationalization, back-office optimization in card production/print-mail, and operational consolidation. James said total $150M split 50/50 over years 2-3.
VRTXVertex Pharmaceuticals1 question · 1 reporting period · 0 of 1 challenging
Calendar 2026 Q1
what are you seeing as a bar for what you would want to see to bring this forward from an efficacy or safety perspective
Show response
Reshma acknowledged AlifTrack has set an extremely high bar: 90% of patients below diagnostic threshold, two-thirds below normal sweat chloride, once-daily dosing. Advancing VX-828/581/2272 requires demonstrable improvement over this profile.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| IQV IQVIA | 2 | —Rate withheld: fewer than 3 questions |
| FIS Fidelity National Information Services | 1 | —Rate withheld: fewer than 3 questions |
| VRTX Vertex Pharmaceuticals | 1 | —Rate withheld: fewer than 3 questions |
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2025 Q1 | 1 | 0%none of 1 question | 1 |
| 2025 Q2 | 1 | 0%none of 1 question | 1 |
| 2025 Q3 | No questions recorded | — | — |
| 2025 Q4 | No questions recorded | — | — |
| 2026 Q1 | 2 | 0%none of 2 questions | 2 |
- 2025 Q11 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q21 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q3No questions recorded
- 2025 Q4No questions recorded
- 2026 Q12 questions · challenge rate 0% (none of 2 questions) · 2 companies
Topics
Topics tagged on this analyst’s questions.
- Revenue Growth2
- Demand2
- Innovation & R&D1
- Competitive Dynamics1
- M&A1
- Cost Pressure1